AP
TEVA icon

Archon Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Archon Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-634,000
Closed -$6.28M – 58
2021
Q2 		$6.28M Sell
634,000
-300,000
-32% -$3.18M 0.79% 42
2021
Q1 		$10.8M Buy
+934,000
New +$10.7M 1.51% 30

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Archon Partners's TEVA Position: Q3 2021 in Review

Archon Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2021, closing a stake of 634,000 shares — an estimated $6.28M sold.

Archon Partners first reported a position in TEVA in Q1 2021 and held it in 2 quarters. The position peaked at $10.8M in Q1 2021. 429 funds tracked by Wall St. Rank hold TEVA as of Q3 2021.

  • Archon Partners reported no remaining Teva Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Archon Partners sold 634,000 Teva Pharmaceuticals shares in Q3 2021, an estimated $6.28M.
  • Archon Partners first reported a position in Teva Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Archon Partners's Teva Pharmaceuticals position peaked at $10.8M in Q1 2021.
  • 429 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2021.

Based on Archon Partners's 13F filing for Q3 2021, filed 15 Nov 2021.